AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
The current AbbVie(ABBV) stock price is $254.49, with a market capitalization of 449.7B. The stock trades at a price-to-earnings (P/E) ratio of 125.47 and offers a dividend yield of 2.65%.
On 2026-07-17, AbbVie(ABBV) stock traded between a low of $254.29 and a high of $260.84. Shares are currently priced at $254.49, which is +0.1% above the low and -2.4% below the high.
AbbVie(ABBV) shares are trading with a volume of 6.8M, against a daily average of 6.52M.
During the past year, AbbVie(ABBV) stock moved between $184.63 at its lowest and $261.64 at its peak.
During the past year, AbbVie(ABBV) stock moved between $184.63 at its lowest and $261.64 at its peak.
ABBV News
...
AbbVie (ABBV) unit, Allergan Aesthetics, announced on Friday that the European Commission approved its anti-wrinkle therapy, Boey, for the temporary improvement...
AbbVie ABBV is scheduled to report second-quarter 2026 results on July 31, before the opening bell. While investor focus will primarily remain on the continued...
Analyst ratings
75%
of 32 ratingsMore ABBV News
AbbVie stock has returned 150.7% over the past five years, yet its current checks present a split picture, with an intrinsic value estimate from a Discounted Ca...
Johnson & Johnson shares fell Tuesday despite a mostly strong second-quarter earnings report and an increase to its full-year guidance. We're not rattled by the...
Abbvie (ABBV) announced an update on their ongoing clinical study. TipRanks has entered a new arena in the investing world, powering the index of an ETF based...
AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's per...
Citi analyst Geoff Meacham raised the firm’s price target on AbbVie (ABBV) to $260 from $230 and keeps a Neutral rating on the shares. The firm adjusted targets...
SkinMedica, a division of AbbVie (NYSE:ABBV), is increasing its focus on regenerative science through new investments. The company is establishing a Regenerati...
AbbVie (ABBV) declines 1.30% to $244.78 in Tuesday afternoon trading, on track for its seventh straight session of losses. Over the past six trading sessions,...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.